Acute Infection Test Articles & Analysis: Older
11 news found
Inflammatix is poised to address important unmet needs in the diagnosis of acute illness, which will result in improved treatment decisions and outcomes. ...
The new funding will be used for continued development and clinical studies to support FDA clearance of the ViraBac EZTM test, which reads gene expression patterns in the immune system to identify whether a suspected infection is bacterial or viral. ...
The company is developing other host-response diagnostic tests that identify the presence and type of infection (viral or bacterial) and predict the risk of severe disease, which could enable physicians to make more informed decisions for patients with acute infection and sepsis. All tests will run on the ...
CVS Pharmacy, the retail division of CVS Health (NYSE: CVS), today announced the availability of three over-the-counter COVID-19 testing options in stores and online. The tests include the Ellume COVID-19 Home Test, the Abbott BinaxNOW COVID-19 Antigen Self Test and the Pixel by Labcorp PCR Test Home Collection ...
” “This is an important stage of Inflammatix’s growth as the company advances its first product – the InSep acute infection and sepsis test – towards commercialization and continues development of its deep pipeline. I am excited to join Tim and our talented team as we unleash the power of immune-response ...
The funds will enable regulatory clearance and global commercialization of the Myrna system, and the InSep™ acute infection and sepsis test, which is designed to enable improved triage and decision-making in the emergency department and other acute care settings. Funds will also support continued development of the ...
Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, to further develop its point-of-care test and system to diagnose infection by reading the immune system. The contract is part of a BARDA contract worth up to $72 million, if all options are exercised. ...
The company is developing other host-response diagnostic tests that identify the presence and type of infection (viral or bacterial), in addition to predicting the risk of severe disease, to enable physicians to make more informed decisions for patients with acute infection and sepsis. ...
Fonseca will oversee Inflammatix’s molecular assay development and engineering teams as the company advances its rapid tests for acute infections, sepsis, and COVID-19 risk stratification. ...
The molecular classifier used in the study forms the basis of Inflammatix’s HostDx rapid tests, which the company is developing to overcome traditional challenges of diagnosing acute infections and sepsis. ...
Financing will be used to advance HostDx tests for acute infections and sepsis to commercial launch in 2021. ...